RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Research and Development

A collection of news and information related to Research and Development published by this site and its partners.

Top Research and Development Articles see all

Displaying items 1-5
  • The increasing irrelevance of corporate nationality [Commentary]

    The increasing irrelevance of corporate nationality [Commentary]
    "You shouldn't get to call yourself an American company only when you want a handout from the American taxpayers," President Obama said last week.
  • Physicists, others using science to help art of film animation

    Physicists, others using science to help art of film animation
    In a small, utilitarian office in Glendale, Ron Henderson methodically jotted down equations for Isaac Newton's Three Laws of Motion on a whiteboard next to his desk. The equations, the physicist explained, are the mathematical building blocks for...

    Most of Allergan's 1,500 job cuts will be in Southern California

    Most of Allergan's 1,500 job cuts will be in Southern California
    Most of the 1,500 job cuts that Botox maker Allergan Inc. announced Monday morning will be made in Southern California, the company’s chief executive said. Allergan plans to eliminate 650 research and development jobs, the bulk of them at its...

    Allergan employees, Irvine officials worried over Valeant offer

    Allergan employees, Irvine officials worried over Valeant offer
    Wall Street sharks are not the only ones keeping a close watch on the contentious battle for control of Allergan Inc., the Irvine company that makes Botox. So are thousands of the company's scientists and researchers, many of whose jobs may be at risk....

    Allergan questions viability, experience of would-be buyer Valeant

    A day before would-be buyer Valeant Pharmaceuticals is set to unveil a second, unsolicited takeover bid, its acquisition target, Allergan Inc., sought to discredit the company by filing a presentation with regulators questioning the viability of Valeant's...